The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1312
ISSUE1312
May 18, 2009
Febuxostat (Uloric) for Chronic Treatment of Gout
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Febuxostat (Uloric) for Chronic Treatment of Gout
May 18, 2009 (Issue: 1312)
Febuxostat (Uloric - Takeda), a xanthine oxidase inhibitor, has been approved by the FDA for chronic management of hyperuricemia in patients with gout. It is the first drug marketed for treatment of gout in 40 years. Febuxostat is structurally...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.